Myanmar vs Vietnam: Average cost of drugs for extensively drug-resistant tuberculosis
Myanmar
963 constant 2022 US$
in 2024
Vietnam
807 constant 2022 US$
in 2024
Myanmar rank
43rd
Vietnam rank
46th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Myanmar
- Vietnam
How they compare
Myanmar currently reports 963 constant 2022 US$ against 807 constant 2022 US$ in Vietnam, a difference of 156 constant 2022 US$.
That makes Myanmar's figure about 1.2 times Vietnam's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Myanmar ahead.
Myanmar ranks 43rd and Vietnam ranks 46th of 56 countries.
Myanmar has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Myanmar | Vietnam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,630 constant 2022 US$ | 4,643 constant 2022 US$ | 2,987 constant 2022 US$ | Myanmar |
| 2020s | 2,689 constant 2022 US$ | 1,873 constant 2022 US$ | 815.6 constant 2022 US$ | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Myanmar or Vietnam?
- Myanmar, at 963 constant 2022 US$ against 807 constant 2022 US$ in Vietnam as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Myanmar and Vietnam?
- 156 constant 2022 US$, with Myanmar ahead.
- How many years of comparable data are there for Myanmar and Vietnam?
- 8 years are reported by both, from 2017 to 2024.
- How do Myanmar and Vietnam rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Myanmar ranks 43rd and Vietnam ranks 46th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.